A Novel Treatment Approach to Silent Hypoxia in COVID-19 Patients
PARK CITY, Utah, May 26, 2020 (SEND2PRESS NEWSWIRE) — Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients’ lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties.